Notice: This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OASM vs. TLPH, FLGC, EGRX, KPRX, AIMD, CLRB, RLMD, PRPH, JAGX, and AYTUShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include Talphera (TLPH), Flora Growth (FLGC), Eagle Pharmaceuticals (EGRX), Kiora Pharmaceuticals (KPRX), Ainos (AIMD), Cellectar Biosciences (CLRB), Relmada Therapeutics (RLMD), ProPhase Labs (PRPH), Jaguar Health (JAGX), and Aytu BioPharma (AYTU). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. Talphera Flora Growth Eagle Pharmaceuticals Kiora Pharmaceuticals Ainos Cellectar Biosciences Relmada Therapeutics ProPhase Labs Jaguar Health Aytu BioPharma Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings. Do analysts prefer OASM or TLPH? Talphera has a consensus target price of $4.33, suggesting a potential upside of 524.40%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Oasmia Pharmaceutical AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oasmia Pharmaceutical AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Do institutionals & insiders have more ownership in OASM or TLPH? 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 3.2% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to OASM or TLPH? In the previous week, Talphera had 9 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 9 mentions for Talphera and 0 mentions for Oasmia Pharmaceutical AB (publ). Talphera's average media sentiment score of 0.49 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that Talphera is being referred to more favorably in the news media. Company Overall Sentiment Oasmia Pharmaceutical AB (publ) Neutral Talphera Neutral Which has more risk & volatility, OASM or TLPH? Oasmia Pharmaceutical AB (publ) has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Which has stronger valuation & earnings, OASM or TLPH? Talphera has higher revenue and earnings than Oasmia Pharmaceutical AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOasmia Pharmaceutical AB (publ)$220K13.63-$18.95MN/AN/ATalphera$650K18.18-$18.40M-$0.69-1.01 Does the MarketBeat Community believe in OASM or TLPH? Oasmia Pharmaceutical AB (publ) received 117 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote. CompanyUnderperformOutperformOasmia Pharmaceutical AB (publ)Outperform Votes12665.97% Underperform Votes6534.03% TalpheraOutperform Votes9100.00% Underperform VotesNo Votes Is OASM or TLPH more profitable? Talphera has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets Oasmia Pharmaceutical AB (publ)-8,633.64% -43.94% -28.92% Talphera N/A -118.46%-65.82% SummaryTalphera beats Oasmia Pharmaceutical AB (publ) on 13 of the 17 factors compared between the two stocks. Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.00M$6.92B$5.61B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.1189.6917.66Price / Sales13.63351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book0.065.335.134.73Net Income-$18.95M$157.56M$118.85M$225.42M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.04flatN/AN/A$3.00M$220,000.000.0057TLPHTalphera3.2335 of 5 stars$0.70+3.2%$4.50+541.0%-32.6%$11.96M$650,000.00-1.0219Analyst ForecastShort Interest ↓News CoverageFLGCFlora Growth2.6031 of 5 stars$0.82-4.5%$5.00+508.3%-34.8%$11.86M$64.15M0.00280Short Interest ↓News CoveragePositive NewsEGRXEagle PharmaceuticalsN/A$0.90-8.2%N/A-85.4%$11.69M$316.61M0.00100Gap DownKPRXKiora Pharmaceuticals3.9467 of 5 stars$3.80-0.8%$10.00+163.2%-24.7%$11.49M$16M0.0010Positive NewsAIMDAinos0.4476 of 5 stars$0.81+1.4%N/A-27.4%$11.41M$120,000.000.0040Short Interest ↑Gap DownCLRBCellectar Biosciences1.9605 of 5 stars$0.27+4.8%$17.67+6,421.5%-93.7%$11.18MN/A-0.1610Analyst ForecastShort Interest ↑News CoverageRLMDRelmada Therapeutics4.5845 of 5 stars$0.37-6.2%$4.25+1,064.4%-91.1%$11.01MN/A-0.1310Short Interest ↓PRPHProPhase Labs3.3416 of 5 stars$0.45-17.6%$11.00+2,371.4%-91.1%$10.63M$44.38M-0.35130Short Interest ↑Gap DownJAGXJaguar Health0.2158 of 5 stars$0.89+3.6%N/A-86.4%$10.50M$9.76M0.0050Short Interest ↑AYTUAytu BioPharma1.3999 of 5 stars$1.70flatN/A-41.1%$10.46M$81M-1.38160Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies TLPH Competitors FLGC Competitors EGRX Competitors KPRX Competitors AIMD Competitors CLRB Competitors RLMD Competitors PRPH Competitors JAGX Competitors AYTU Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OASM) was last updated on 1/31/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
